20(S)-Protopanaxatriol Reference: 29073-25 An active ginsenoside metabolite; cytotoxic to HL-60 cancer cells (IC50 = 16 µM); inhibits the proliferation of HUVECs (EC50 = 6.64 µg/ml); blocks LPS-induced increases in the protein levels of COX-2 and iNOS and decreases LPS-induced NF-κB activity in RAW 264.7 cells from 1-20 µM
R-(-)-Phenylephrine (hydrochloride) Reference: 18619-250 An adrenergic α1A receptor agonist (Ki = 1.4 µM) that demonstrates selectivity against the α1B and α1C receptor subtypes (Kis = 23.9 and 47.8 µM, respectively); frequently used to precontract smooth muscle in preparations designed to study the properties of various vasodilator agents
20(S)-Protopanaxatriol Reference: 29073-5 An active ginsenoside metabolite; cytotoxic to HL-60 cancer cells (IC50 = 16 µM); inhibits the proliferation of HUVECs (EC50 = 6.64 µg/ml); blocks LPS-induced increases in the protein levels of COX-2 and iNOS and decreases LPS-induced NF-κB activity in RAW 264.7 cells from 1-20 µM
R-(-)-Phenylephrine (hydrochloride) Reference: 18619-50 An adrenergic α1A receptor agonist (Ki = 1.4 µM) that demonstrates selectivity against the α1B and α1C receptor subtypes (Kis = 23.9 and 47.8 µM, respectively); frequently used to precontract smooth muscle in preparations designed to study the properties of various vasodilator agents
Lyso-globotetraosylceramide (d18:1) Reference: 29134-1 A form of Gb4 lacking the fatty acyl group; binds to VTE in a glycolipid binding assay; acylated to stearic acid via a condensation reaction by sphingolipid ceramide N-deacylase to form a ceramide
R-(-)-Phenylephrine (hydrochloride) Reference: 18619-500 An adrenergic α1A receptor agonist (Ki = 1.4 µM) that demonstrates selectivity against the α1B and α1C receptor subtypes (Kis = 23.9 and 47.8 µM, respectively); frequently used to precontract smooth muscle in preparations designed to study the properties of various vasodilator agents
Dehydrocholic Acid Reference: 29176-1 A synthetic bile acid and a derivative of cholic acid; increases bile flow by 2.7-fold and decreases biliary levels of phospholipids, cholesterol, and bilirubin in conscious dogs at 50 mg/kg; increases bile flow by 253% at 1 µmol/min/0.1 kg and decreases the secretion rate of phospholipids and cholesterol by 64 and 94%, respectively, in rats when infused intravenously at 2 µmol/min/0.1 kg
BRL 37344 (sodium salt) Reference: 18622-1 A selective agonist of β3-adrenergic receptors with Ki values of 0.43, 9.17, and 37.9 µM for β3, β2, and β1, respectively